VYNE Therapeutics (VYNE) Asset Writedowns and Impairment (2020 - 2021)
VYNE Therapeutics (VYNE) posted Asset Writedowns and Impairment of $1.6 million for Q4 2021, down 97.06% on a QoQ basis from $54.3 million in Q2 2020.
VYNE Therapeutics (VYNE) Asset Writedowns and Impairment (2020 - 2021) Analysis & Trends
VYNE Therapeutics' Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $1.6 million for Q4 2021.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $1.6 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $1.6 million (down 97.06% YoY) and the FY2021 annual result came in at $1.6 million, down 97.06% from the prior year.
- Asset Writedowns and Impairment was $1.6 million for Q4 2021 at VYNE Therapeutics, down from $54.3 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $54.3 million in Q2 2020 and bottomed at $1.6 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 1.60 Mn |
| Dec 31, 2021 | 1.60 Mn |
| Jun 30, 2020 | 54.35 Mn |
| Jun 30, 2020 | 54.35 Mn |